TROPION-Lung01 Study Design and Baseline demographics
TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously
treated non-small cell lung cancer with actionable genomic alterations
Luis Paz-Ares,¹ Myung-Ju Ahn,² Aaron Lisberg,³ Satoru Kitazono, 4 Byoung Chul Cho, 5 George Blumenschein Jr, Elaine Shum, 7 Elvire Pons Tostivint, Yasushi Goto,⁹ Kiyotaka
Yoh,10 Rebecca Heist, 11 Paul Baas, 12 David Planchard, 13 Maurice Pérol, 14 Enriqueta Felip, 15 Wu-Chou Su, 16 Hong Zebger-Gong, 17 Lan Lan, 18 Chelsea Liu, 18 Jacob Sands 19
¹Hospital Universitario 12 de Octubre, Madrid, Spain; 2Samsung Medical Center, Seoul, South Korea; ³David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 4The Cancer Institute Hospital of JFCR, Tokyo, Japan;
5Severance Hospital, Seoul, South Korea; 6The University of Texas MD Anderson Cancer Center, Houston, TX, USA; NYU Langone Health Perlmutter Cancer Center, New York, NY, USA; University Hospital of Nantes, Nantes,
France; National Cancer Center Hospital, Tokyo, Japan; 10National Cancer Center Hospital East, Kashiwa, Japan; 11Massachusetts General Hospital Cancer Center, Boston, MA, USA; 12The Netherlands Cancer Institute, Amsterdam,
the Netherlands; 13 Gustave Rouss, Villejuif, France; 14Centre Léon Bérard, Lyon, France; 15Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; 16 National Cheng Kung University Hospital,
Tainan, Taiwan; 17Daiichi Sankyo Europe GmbH, Munich, Germany; 18Daiichi Sankyo, Inc, Basking Ridge, NJ, USA; 19Dana-Farber Cancer Institute, Boston, MA, USA
Daiichi-Sankyo
17View entire presentation